Alcista
$605.58
Precio del escenario
$420.240
-1.807 (-0.43%)Al cierre
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
Intuitive Surgical Inc is a good buy right now due to its current price of $423.96 being below analyst targets of $485 and $500, indicating significant upside potential. The company has shown a strong revenue growth of 20.5% year-over-year, with a robust gross margin of 67.78% in the latest quarter, suggesting solid profitability. However, a risk to consider is the RSI at 74.78, indicating that the stock may be overbought in the short term.
BTIG
$454
2026-10-12
BTIG
2026-10-12
Precio objetivo
$454
Barclays
$485
2026-10-06
Barclays
2026-10-06
Precio objetivo
$485
Oppenheimer
—
2026-08-12
Oppenheimer
2026-08-12
Precio objetivo
—
HSBC
$391
2026-07-30
HSBC
2026-07-30
Precio objetivo
$391
UBS
$500
2026-07-28
UBS
2026-07-28
Precio objetivo
$500
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Healthcare Investors' Dilemma: Abbott vs. Intuitive Surgical

Intensifying Competition in Pharma Sector: Investor Focus Required

Five Ways to Invest in Physical AI

Johnson & Johnson's Future Growth Potential Analysis

Investors Concerned About Equity Market Valuations
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Intuitive Surgical Inc is a good buy right now due to its current price of $423.96 being below analyst targets of $485 and $500, indicating significant upside potential. The company has shown a strong revenue growth of 20.5% year-over-year, with a robust gross margin of 67.78% in the latest quarter, suggesting solid profitability. However, a risk to consider is the RSI at 74.78, indicating that the stock may be overbought in the short term.
17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.


$ISRG Barclays initiates coverage with an Overweight rating and a $485 target price.
Mostrar más
$ISRG The long-term technical setup for this med device stock is excellent.
Mostrar más

$ISRG remains under pressure, with all moving averages pointing down. Buyers are hesitant, waiting for better entry points in the current environment. The market is punishing quality compounders, but patience is key here. EPS growth should continue regardless of short-term noise.
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.